Halofuginone Hydrobromide

N/A

Report date: 2023/04/25 13:50:32
NME

Base Information

Drug NameHalofuginone Hydrobromide
Drug Alias Namehalofuginona氢溴酸常山酮halofuginonum氢溴常山酮氢溴酸卤夫酮 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsCollagen inhibitors
TargetsCollagen
Therapy Area/IndicationsMuscular Dystrophy, DuchenneSarcoma, Kaposi
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAkashi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAkashi Therapeutics IncProcessa Pharmaceuticals IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, DuchenneSarcoma, Kaposi

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG